Cancer Stem Cell for Tumor Therapy

Huang, Binjie; Yan, Xin; Li, Yumin

doi:10.3390/cancers13194814

Cited by 25 publications

(23 citation statements)

References 188 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Spontaneous or acquired resistance to conventional and molecularly targeted therapy, and potential cross-resistance to individual therapeutic agents represent a formidable challenge for new drug discovery of stem cell targeting compounds [ 12 , 13 , 14 , 47 , 48 , 49 ].…”

Section: Future Researchmentioning

confidence: 99%

Stem Cell Models for Breast and Colon Cancer: Experimental Approach for Drug Discovery

Telang¹

2022

IJMS

View full text Add to dashboard Cite

The progression of the early stages of female breast and colon cancer to metastatic disease represents a major cause of mortality in women. Multi-drug chemotherapy and/or pathway selective targeted therapy are notable for their off-target effects and are associated with spontaneous and/or acquired chemotherapy resistance and the emergence of premalignant chemo-resistant cancer-initiating stem cells. The stem cell populations are responsible for the evolution of therapy-resistant metastatic disease. These limitations emphasize an unmet need to develop reliable drug-resistant cancer stem cell models as novel experimental approaches for therapeutic alternatives in drug discovery platforms. Drug-resistant stem cell models for breast and colon cancer subtypes exhibit progressive growth in the presence of cytotoxic chemo-endocrine therapeutics. The resistant cells exhibit upregulated expressions of stem cell-selective cellular and molecular markers. Dietary phytochemicals, nutritional herbs and their constituent bioactive compounds have documented growth inhibitory efficacy for cancer stem cells. The mechanistic leads for the stem cell-targeted efficacy of naturally occurring agents validates the present experimental approaches for new drug discovery as therapeutic alternatives for therapy-resistant breast and colon cancer. The present review provides a systematic discussion of published evidence on (i) conventional/targeted therapy for breast and colon cancer, (ii) cellular and molecular characterization of stem cell models and (iii) validation of the stem cell models as an experimental approach for novel drug discovery of therapeutic alternatives for therapy-resistant cancers.

show abstract

Section: Future Researchmentioning

confidence: 99%

Stem Cell Models for Breast and Colon Cancer: Experimental Approach for Drug Discovery

Telang¹

2022

IJMS

View full text Add to dashboard Cite

show abstract

“…Together with MSCs, all cancers express specific CSCs, known since 2005 based on their initially discovered properties [47,48]. Subsequent intense studies in recent years, reported here by two recent reviews [49,50], have led to the identification of many specific properties of CSCs and their EVs [9,12,13,[28][29][30][31]. In cancer niches CSCs coexist not only with cells of the MSC family, but also with normal cancer cells and various noncancer cells, such as fibroblasts, macrophages, and immune cells, participating in specific steps of cancer development.…”

Section: Discussionmentioning

confidence: 89%

Cancer Stem Cells, Together with Mesenchymal Stem Cells and Other Cooperative Cells, Govern the Initiation and Development of Cancer

2022

Journal of Experimental Pathology

View full text Add to dashboard Cite

Cancer stem cells, a family expressed by all cancers, are necessary for the origin and critical for the growth of all cancers. In the latter tissue the cancer stem cells are concentrated and operative in small areas called niches, analogous to the stromas of non-cancer tissues. In addition to cancer stem cells, the niches contain normal cancer cells and various types of cooperative non-cancer cells. Most important among the latter are the mesechymal stem cells, analogous to those expressed by non-cancer tissues, that are important, and in some cases necessary for the development of several cancers. Various effects dependent on the already mentioned, two types of stem cells are induced not directly by them, but via their secreted extracellular vesicles, the exosomes and ectosomes. Additional cancer-cooperative cells, concentrated within the niches, include fibroblasts and immune cells that participate in the development of some cancer-relevant processes including angiogenesis. Cancer stem cells govern many critical processes of cancer life, from initiation and progression, including generation and distribution of metastases, therapy resistance, and cancer-relapse, as well as additional severe tissue problems such as efflux of anti-cancer drugs, autophagy, and evasion of immune surveillance. Without their stem cells specific cancers cannot develop. In case of defect, the cancer stem cells are induced by transformation of either normal cancer cells or mesenchymal stem cells. The present knowledge about cancer stem cells and their key effects are of critical importance in the development of therapeutic processes addressed against these cells

show abstract

“…CSCs are the distinct subpopulation of cells which have the ability to self-renew and are not destroyed by conventional treatments. The failure of anticancer treatment has been attributed to tumor recurrence due to CSCs [38]. Targeting CSCs may prevent or delay tumor development, metastasis chemoresistance, and recurrence.…”

Section: Discussionmentioning

confidence: 99%

Resveratrol Analog 4-Bromo-Resveratrol Inhibits Gastric Cancer Stemness through the SIRT3-c-Jun N-Terminal Kinase Signaling Pathway

Tai

Chen

et al. 2021

CIMB

View full text Add to dashboard Cite

Chemotherapy is the treatment of choice for gastric cancer, but the currently available therapeutic drugs have limited efficacy. Studies have suggested that gastric cancer stem cells may play a key role in drug resistance in chemotherapy. Therefore, new agents that selectively target gastric cancer stem cells in gastric tumors are urgently required. Sirtuin-3 (SIRT3) is a deacetylase that regulates mitochondrial metabolic homeostasis to maintain stemness in glioma stem cells. Targeting the mitochondrial protein SIRT3 may provide a novel therapeutic option for gastric cancer treatment. However, the mechanism by which stemness is regulated through SIRT3 inhibition in gastric cancer remains unknown. We evaluated the stemness inhibition ability of the SIRT3 inhibitor 4′-bromo-resveratrol (4-BR), an analog of resveratrol in human gastric cancer cells. Our results suggested that 4-BR inhibited gastric cancer cell stemness through the SIRT3-c-Jun N-terminal kinase pathway and may aid in gastric cancer stem-cell–targeted therapy.

show abstract

Cancer Stem Cell for Tumor Therapy

Cited by 25 publications

References 188 publications

Stem Cell Models for Breast and Colon Cancer: Experimental Approach for Drug Discovery

Stem Cell Models for Breast and Colon Cancer: Experimental Approach for Drug Discovery

Cancer Stem Cells, Together with Mesenchymal Stem Cells and Other Cooperative Cells, Govern the Initiation and Development of Cancer

Resveratrol Analog 4-Bromo-Resveratrol Inhibits Gastric Cancer Stemness through the SIRT3-c-Jun N-Terminal Kinase Signaling Pathway

Contact Info

Product

Resources

About